Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CER 209

Next Previous
Search
Drug Profile

CER 209

Alternative Names: CER-209

Latest Information Update: 11 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cerenis Therapeutics
  • Developer ABIONYX Pharma
  • Class Antihyperlipidaemics; Hepatoprotectants; Vascular disorder therapies
  • Mechanism of Action P2RY13 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Dyslipidaemias; Non-alcoholic steatohepatitis
  • Preclinical Atherosclerosis
  • No development reported Non-alcoholic fatty liver disease

Most Recent Events

  • 10 Apr 2024 CER 209 is still in phase I trials for Dyslipidaemias and Non-alcoholic steatohepatitis in unknown location (ABIONYX pipeline, April 2024)
  • 10 Apr 2024 CER 209 is still in preclinical development for Atherosclerosis in unknown location (ABIONYX pipeline, April 2024)
  • 28 Sep 2023 No recent reports of development identified for preclinical development in Atherosclerosis in Unknown

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top